Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Gross Profit (2023 - 2025)

ImmunityBio (IBRX) has disclosed Gross Profit for 3 consecutive years, with $37.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 401.89% to $37.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $112.5 million, a 663.21% increase, with the full-year FY2025 number at $112.5 million, up 663.21% from a year prior.
  • Gross Profit was $37.9 million for Q4 2025 at ImmunityBio, up from $31.9 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $37.9 million in Q4 2025 to a low of $40000.0 in Q1 2024.
  • A 3-year average of $12.7 million and a median of $6.8 million in 2024 define the central range for Gross Profit.
  • Biggest YoY gain for Gross Profit was 41047.5% in 2025; the steepest drop was 401.89% in 2025.
  • ImmunityBio's Gross Profit stood at $82000.0 in 2023, then soared by 9109.76% to $7.6 million in 2024, then skyrocketed by 401.89% to $37.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Gross Profit are $37.9 million (Q4 2025), $31.9 million (Q3 2025), and $26.3 million (Q2 2025).